Please assess the completion status of the following clinical trial:

Trial Title: A Study of 2-Iminobiotin in Neonates With Perinatal Asphyxia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Neonates with ≥ 36 and \<44 weeks gestation with at least one of the following:~   * Apgar Score ≤ 5 at 10 minutes after birth~  * Continued need for resuscitation, including endotracheal or mask ventilation at 10 minutes after birth~  * Acidosis, defined as either umbilical cord pH or any arterial, venous, capillary pH within 60 minutes of birth pH ≤ 7.00~  * Acidosis, defined as base deficit ≥ 16 mmol/l in umbilical blood sample or any blood sample within 60 minutes of birth (arterial or venous).~2. The presence of moderate/severe encephalopathy defined as:~   * Altered state of consciousness (lethargy, stupor, coma) and at least one of the following:~     * Hypotonia~    * Abnormal reflexes including oculomotor or papillary abnormalities~    * Weak or absent suck reflex~    * Clinical seizures AND~  * Depression of the background pattern (lower margin≤ 5 µV meaning at least DNV or BS, CLV, FT) or the presence of seizure activity on the aEEG, registered for at least 30 minutes within 6h after birth.~3. Presence in hospital and ability to start treatment within 6h after birth.~4. Informed Consent Form signed before first study-related activity according to local law.~5. Receiving standard therapy without hypothermia.~Exclusion Criteria:~1. Major antenatally known- or congenital abnormalities, such as hernia diaphragmatica requiring ventilation.~2. Major antenatally known chromosomal abnormalities, such as trisomy 13 or 18 or neonates with evident syndromal appearances including brain dysgenesis.~3. Severe growth restriction with a birth weight below the 3rd percentile.~4. Inability to insert an indwelling catheter (umbilical venous catheter or percutaneously inserted central catheter, preferably multiple lumen).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Hours
- Healthy Volunteers: f

Study Arms:
- 2-Iminobiotin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).